
Massachusetts high school baseball player celebrates end of radiation treatment with teammates
The baseball field at North Reading High School has been getting a lot of use this season. They've made it to the playoffs after all. But their inspiration to play better and practice harder has come from a teammate who was not on the field this year.
Brady Cullen is a 16-year-old sophomore at NRHS who would normally be finishing a spring season in his position on third base. Last August, he and his family got a devastating diagnosis of a brain tumor (pilocytic astrocytoma.) The non-cancerous tumor was too close to his brain stem to be operated on. After months of appointments, his medical team at Mass General Hospital recommended radiation to stop it from growing.
Brady rings bell after six weeks of radiation
This week, Brady finished his 30th session. Six weeks of radiation, five days a week. When Brady rang the bell in the halls of MGH he wasn't alone.
"It was unbelievable. It was hard not to just break down right there in the hospital," Brady recalled.
When he turned around, he found his entire baseball team lining up in the halls. Cheering him on as he left his last appointment in his months-long battle.
North Reading sophomore Brady Cullen is greeted by his baseball teammates after completing treatment at Mass General Brigham.
Mass General Brigham
"They are my brothers and to see that combined with my family, it was so special," he said. "It just made me realize I am at peace with myself. I am at peace with my journey. I am where I want to be I am where I need to be and that will never change."
Team makes trip to Boston
Eric Archambault is the head coach of the North Reading High School baseball team. Coach Arch, as he's called, said it wasn't a question of whether the team would make the trip to Boston on Thursday. He said Brady never missed school and rarely missed practice or games as a team manager during his treatments.
"We are seeing a kid with our very eyes attack a situation that nobody wishes for, and he takes it head on every single day," said Archambault. "Everyone wasn't supporting Brady just because of the diagnosis. We are supporting Brady because of who he is. He has touched everyone on the team throughout the years, and we look up to him."
Brady said he plans to work with a physical therapist and get back out on the field. Overwhelmed and thankful for the army of support he had from his team and community.
"Life is the most precious and beautiful thing, and it can be taken away so fast and I want them to realize that, embrace hardships because hardships build your character and they build who you are, and they make you stronger than ever," Brady said. "I know for damn sure I am stronger than ever from this. I am proud to say I came out on top with a whole new perspective on live and a new appreciation for it."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
7 minutes ago
- Yahoo
Dave Parker, hard-hitting outfielder nicknamed 'the Cobra,' dies at 74
PITTSBURGH (AP) — Dave Parker, a hard-hitting outfielder who was set to be inducted into the Baseball Hall of Fame next month, has died, the Pittsburgh Pirates announced Saturday. He was 74. No further details about Parker's death were immediately available. The Pirates informed the crowd of his death just before the start of their game against the New York Mets and held a moment of silence. Advertisement Nicknamed 'the Cobra,' the 6-foot-5 Parker made his major league debut in 1973 and played 19 seasons, 11 for the Pirates. He was the NL MVP in 1978, won a World Series with Pittsburgh a year later and then won another championship in 1989 with the Oakland Athletics. Parker won back-to-back batting titles in 1977 and '78. He finished his career as a .290 hitter with 339 homers and 1,493 RBIs. He also played for Cincinnati, Milwaukee, the California Angels and Toronto. Parker was elected to the Hall of Fame by a special committee in December. The induction ceremony in Cooperstown, New York, is set for July 27. ___ AP MLB:
Yahoo
8 minutes ago
- Yahoo
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. "With our expertise in primary hemophagocytic lymphohistiocytosis, we understand the urgency of managing MAS quickly to improve patient outcomes," said Guido Oelkers, Chief Executive Officer at Sobi. "Gamifant is already an established therapy making a meaningful difference for patients with primary HLH, and with this approval, we are excited about the opportunity to positively impact patients affected by MAS in Still's Disease". The approval is based on results of the pooled data from two pivotal studies, the Phase 3 study (NCT05001737) and NI-0501-06 (NCT03311854). 54 percent (21/39) of patients had a complete response at Week 8, and 82% (32/39) achieved clinical MAS remission (VAS ≤1 cm) at Week 8. Safety and tolerability were consistent with previous clinical studies. In patients with HLH/MAS in Still's disease, the most common adverse events (≥20%) were viral infections, including cytomegalovirus infection or reactivation, and rash. "MAS in Still's disease is a serious and potentially life-threatening complication, marked by severe hyperinflammation and, in some cases, multi-organ failure," said Alexei A. Grom, MD, Professor of Pediatrics, Research Director Division of Rheumatology, Cincinnati Children's Hospital Medical Center. "Many patients affected by MAS—both young children and adults—face significant unmet medical needs. With Gamifant now as the first FDA-approved treatment for MAS, we have a new therapeutic option that helps control hyperinflammation and reduce our reliance on high-dose glucocorticoids." MAS, a form of HLH, is a severe complication of rheumatic diseases, occurring most frequently in Still's disease including systemic juvenile idiopathic arthritis and adult-onset Still's disease. HLH/MAS is a rare systemic disorder of interferon gamma (IFNy) driven hyperinflammation with common clinical manifestations such as high persistent fever, elevated ferritin, cytopenias, coagulopathies, and hepatosplenomegaly. Gamifant, an interferon gamma (IFNγ)–blocking antibody, is the first and only FDA approved treatment for adult and pediatric (newborn and older) patients with primary HLH with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. U.S. Indication for Gamifant® (emapalumab-lzsg) Please see the full Prescribing Information for Gamifant. About macrophage activation syndrome (MAS) Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently in Still's disease including systemic juvenile idiopathic arthritis (sJIA) – a rare systemic disorder of auto-inflammatory nature with common clinical manifestations such as daily spiking fever, typical transient cutaneous rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities and hyperferritinaemia, possibly progressing to multiple organ failure and death. MAS is classified as a secondary form of haemophagocytic lymphohistiocytosis (HLH). About Gamifant® (emapalumab-lzsg) Gamifant® (emapalumab-lzsg) is the only approved anti-interferon gamma (IFNγ) monoclonal antibody. Gamifant works by binding to and neutralizing IFNγ. When IFNγ is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour. Gamifant is approved in the US for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 28 June 2025 at 00:55 CEST. Gerard TobinHead of Investor Relations This information was brought to you by Cision The following files are available for download: FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease View original content: Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
2025 Southwick Motocross 250 Moto 2: LIVE Updates
Haiden Deegan swept three of the first four motos and he is poised to do so again at The Wick 338 in Southwick, Massachusetts. MX 2025 Rd 05 Southwick Haiden Deegan Haiden Deegan wins Southwick Moto 1 by 25 seconds over Levi Kitchen Haiden Deegan held a 17-second lead over Michael Mosiman on Lap 8. Advertisement Dan Beaver , Keep an eye on Jo Shimoda in Moto 2. He won this race in each of the last two seasons. MX 2025 Rd 04 High Point Haiden Deegan 2025 Southwick Motocross 250 Qualification: Haiden Deegan yards the field in both sessions Haiden Deegan was more than two seconds faster than Tom Vialle in the first qualification session. Dan Beaver , More SuperMotocross News Jett Lawrence runs away from Southwick Moto 1 field Southwick 450 Qualification | 250 Qualification Justin Barcia to return from knee injury in Southwick Drew Adams sidelined with broken finger Jo Shimoda highlights Japanese MXoN team Southwick Preview | Betting odds Chad Reed among 2025 AMA HoF inductees Chance Hymas out for remainder of 2025 High Point 450 Results | 250 Results Jett Lawrence wins High Point overall; Eli Tomac takes Moto 2 Haiden Deegan shrugs off last week, sweeps High Point